Chronic inducible urticaria spans many subtypes and frequently overlaps with chronic spontaneous urticaria, making careful history taking and pragmatic provocation testing central to an accurate diagnosis.
Back
From Avoidance to Action: Emerging Therapies for Management of Chronic Inducible Urticaria
Dermatologists review chronic inducible urticaria subtypes, diagnosis, and quality-of-life burden; the limits of trigger avoidance and antihistamines; and the evolving advanced-therapy landscape, including the phase 3 REMIND data and new approval in symptomatic dermographism, safety, guideline positioning, switching strategies, and emerging mast cell–targeted mechanisms.
From Avoidance to Action: Emerging Therapies for Management of Chronic Inducible Urticaria
Episodes
All
All
Targeted laboratory testing and an understanding of the type I and type IIb immune pathways help clinicians characterize CIndU and explain to patients why their skin reacts the way it does.
Advertisement
Advertisement
Trending on HCPLive
1
TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk
2
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
3
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
4
Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD
5